A Phase IV, Multi-center, Open-label, Single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Study of 16 Weeks Treatment With Androderm in Hypogonadal Men
Latest Information Update: 13 Jul 2022
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Adverse reactions
- Sponsors AbbVie; Allergan
Most Recent Events
- 29 Jun 2021 Status changed from active, no longer recruiting to completed.
- 16 Jun 2021 Planned End Date changed from 15 Jun 2021 to 24 Jun 2021.
- 16 Jun 2021 Planned primary completion date changed from 15 Jun 2021 to 24 Jun 2021.